Autres langues Luye Pharma Group Ltd.

Actions

2186

BMG570071099

Temps Différé Hong Kong S.E. Autres places de cotation 03:52:05 06/05/2024			Varia. 5j.	Varia. 1 janv.
2,95 ^HKD	-2,32 %		+7,27 %	-20,91 %

27/03	Luye Pharma Group Ltd. publie ses résultats pour l'exercice clos le 31 décembre 2023	CI
07/03	Le groupe Luye Pharma annonce le lancement de son médicament innovant Zepzelca® (Lurbinectedin) pour le traitement du SCLC à Hong Kong et à Macao	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	07/03
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug	04/03
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	04/03
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%	02/02
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	01/02
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List	13/12
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	13/12
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong	12/12
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	12/12
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	12/12
Luye Pharma Group Ltd. Announces Board Changes	06/12
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05/12
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug	04/12
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	04/12
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease	01/11
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease	01/11
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	31/10/23
Luye Pharma Files New Drug Application in US for Schizophrenia Medication	09/10/23
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	09/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Luye Pharma Group Ltd.

Actions

2186

BMG570071099

Autres langues

Filtres